Research Topics
Genomes and GenesSpecies | M SchwabSummaryAffiliation: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology Country: Germany Publications
| Collaborators
|
Detail Information
Publications
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinomaElke Schaeffeler
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
Genome Med 3:82. 2011..Therefore, we investigated the role of DNA methylation in the transcriptional regulation of the family members SLC22A1/OCT1, SLC22A2/OCT2 and SLC22A3/OCT3 in HCC...
Organic anion transporters and their implications in pharmacotherapyArian Emami Riedmaier
Margarete Fischer Bosch Institute of Clinical Pharmacology, 70 376 Stuttgart, Auerbachstr 112, Germany
Pharmacol Rev 64:421-49. 2012....
Prediction of breast cancer by profiling of urinary RNA metabolites using Support Vector Machine-based feature selectionCarsten Henneges
Center for Bioinformatics Tübingen ZBIT, Sand 1, D 72076 Tubingen, Germany
BMC Cancer 9:104. 2009....
Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosisM Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Med Pediatr Oncol 31:159-65. 1998..An association of this triad of findings no longer appears to be accidental...
Genetic polymorphisms of the human MDR1 drug transporterMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Annu Rev Pharmacol Toxicol 43:285-307. 2003..Potential implications of MDR1 polymorphisms for drug disposition, drug effects, and disease risk are discussed...
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphismMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 12:429-36. 2002....
[Pharmacogenomics: hype or hope?]M Schwab
Dr Margarete Fischer Bosch Institut für Klinische Pharmakologie, Universitatsklinikum Tubingen, Auerbachstrasse 112, 70376 Stuttgart
Dtsch Med Wochenschr 136:461-7. 2011..The implementation of pharmacogenomics into clinical practise is a momentous future challenge that requires the establishment of interdisciplinary networks and professional organizations...
Using trade names: a risk factor for accidental drug overdoseMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Arch Intern Med 162:1065-6. 2002..This case illustrates that the use of trade names, omitting the international nonproprietary names of the active moiety, carries the risk of serious adverse drug events by overdose...
Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's diseaseK R Herrlinger
Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
Aliment Pharmacol Ther 19:1269-76. 2004..Tioguanine (thioguanine) therapy results in much higher levels of 6-thioguanine-nucleotide levels when compared with azathioprine or mercaptopurine...
Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizoleT Saussele
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 82:265-74. 2007..These data warrant further studies to elucidate the drug-interaction potential of metamizole, especially in patients with long-term treatment...
High-throughput genotyping of thiopurine S-methyltransferase by denaturing HPLCE Schaeffeler
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany
Clin Chem 47:548-55. 2001..Additionally, DHPLC allows a simultaneous screening for novel genetic variability in the TPMT gene...
Remission maintenance by tioguanine in chronic active Crohn's diseaseK R Herrlinger
Robert Bosch Hospital, Stuttgart, Germany
Aliment Pharmacol Ther 17:1459-64. 2003..Tioguanine may offer an alternative for immunosuppression in chronic active Crohn's disease. Recently, we have shown that tioguanine is effective in inducing rapid remission...
CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pyloriMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Clin Pharmacol Ther 76:201-9. 2004..This study tests the hypothesis that CYP2C19 wild type ( wt/wt ) in white patients is also associated with a higher probability of treatment failure...
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Mikko Niemi
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 14:429-40. 2004..No significant associations were found between OATP-B, MRP2 or MDR1 polymorphisms and the pharmacokinetics of pravastatin. These results suggest that haplotypes are more informative in predicting the OATP-C phenotype than single SNPs...
A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone diseaseOlga Renner
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany
PLoS ONE 4:e7321. 2009..In this study the SLC10A2 gene was investigated to identify novel genetic variants and their association with gallstone formation...
Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoformsO Burk
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Germany
Br J Pharmacol 167:666-81. 2012..Here, we explore the capacity of antimalarial drugs to induce drug metabolism via activation of constitutive androstane receptors (CAR) by ligand binding...
Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptorE Hoffart
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Tubingen, Germany
Br J Pharmacol 165:1595-608. 2012..We here investigate whether they exert differential effects on the induction of these genes via activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR)...
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitisK R Herrlinger
Department of Gastroenterology, Hepatology and Endocrinology, Robert Bosch Hospital, Stuttgart, Germany
Clin Pharmacol Ther 89:422-8. 2011..We suggest that ABCB1, but not CYP3A5, may predict short-term remission of Tac in steroid-refractory UC...
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic dataMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 78:627-34. 2005..We tested whether esomeprazole-induced healing of gastroesophageal reflux disease (GERD) is related to CYP2C19 genotype...
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitisMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
Gastroenterology 124:26-33. 2003..Because the MDR1 single nucleotide polymorphism C3435T is associated with lower intestinal P-glycoprotein expression, we tested whether this polymorphism predisposes to development of ulcerative colitis...
A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancerMatjaz Rokavec
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and Department of Gynecology, Robert Bosch Hospital, Stuttgart, Germany
Cancer Res 68:9799-808. 2008..35; 95% CI, 1.34-4.14). Our functional and patient-based results suggest that the TC21 -582C>T polymorphism improves prediction of tamoxifen treatment outcome in breast cancer...
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's diseaseMaureen J Koslowski
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
PLoS ONE 4:e4496. 2009..38, 95% CI 1.03 to1.84, p = 0.02882). The newly identified genetic association of TCF-4 with ileal CD provides evidence that the decrease in Paneth cell alpha-defensins is a primary factor in disease pathogenesis...
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cellsM Hitzl
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 11:293-8. 2001..Measurement of rhodamine efflux using flow-cytometry from peripheral blood cells allows assessment of genetically determined differences in P-glycoprotein function...
Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6U M Zanger
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 11:573-85. 2001..2, in comparison to 2D6.1, whereas only modest Km changes were observed. Taken together, these data provide further insight into the complex mechanisms that govern the highly variable expression and function of CYP2D6...
Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme functionElke Schaeffeler
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Hum Mutat 27:976. 2006..In Caucasians the occurrence of these genetic variants appears to be extremely rare since none of these alleles were identified in a randomly selected control population of 1048 individuals...
Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugationMonika Bredschneider
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 71:479-87. 2002....
Pharmacogenomics of tamoxifen therapyHiltrud Brauch
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Chem 55:1770-82. 2009..Tamoxifen is a standard endocrine therapy for the prevention and treatment of steroid hormone receptor-positive breast cancer...
CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCRElke Schaeffeler
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Hum Mutat 22:476-85. 2003..The predictability of the new strategy was systematically evaluated. The semiautomatic TaqMan assay allows high sample throughput and will be useful for pharmacogenetic studies and in the clinical setting...
Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's diseaseTaku Furuno
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376 Stuttgart, Germany
Pharmacogenetics 12:529-34. 2002..In conclusion, MDR1 and other drug transporters represent plausible candidates as Parkinson's disease risk genes. Larger studies are required to confirm this role in the etiology of Parkinson's disease...
The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxinO Burk
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 88:685-94. 2010..In conclusion, thyroid abnormalities can exert significant effects on the expression of P-glycoprotein, thereby altering the disposition and action of drugs that are substrates of P-glycoprotein...
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivoS Riedmaier
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 87:65-73. 2010..The potential of UGT genotyping to identify patients who are at increased risk for failure of therapy and/or adverse effects of statins warrants further investigation...
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasmaT E Mürdter
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 89:708-17. 2011..For other enzymes tested, carriers of reduced-function CYP2C9 (*2, *3) alleles had lower plasma concentrations of active metabolites (P < 0.004), pointing to the role of additional pathways...
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjectsSebastian Raimundo
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacol Ther 76:128-38. 2004..Their identification is clinically relevant but remains unsatisfactory because of incomplete characterization of the major allele involved, termed CYP2D6*41 (-1584C, R296C, S486T)...
Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1)Monika Hitzl
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 14:309-18. 2004..Taken together, the MDR1 polymorphisms C3435T and G2677T are associated with altered P-glycoprotein expression in the human placenta, and may have clinical consequences due to genetically determined, variable drug exposure of the fetus...
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenzKathrin Klein
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenet Genomics 15:861-73. 2005..17 (T26S, D28G, R29T) appeared to be functionally normal. These data extend the CYP2B6 knowledge base and should be particularly relevant for anti-HIV-therapy with efavirenz...
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidationAna M Gomes
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Auerbachstrasse 112, 70376 Stuttgart, Germany
Pharmacogenomics 10:579-99. 2009..We investigated genetic and nongenetic POR variability and its impact on drug-oxidation activities in human liver microsomes...
Pharmacokinetic considerations in the treatment of inflammatory bowel diseaseM Schwab
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacokinet 40:723-51. 2001..No accumulation was observed when it was administered at intervals of 4 or 8 weeks. Methotrexate may reduce the clearance of infliximab from serum...
Telomere length in different tissues of elderly patientsU Friedrich
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
Mech Ageing Dev 119:89-99. 2000..Furthermore, our results indicate that TRF measurement in easily accessible tissues such as blood could serve as a surrogate parameter for the relative telomere length in other tissues...
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometryUte Hofmann
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
J Chromatogr B Analyt Technol Biomed Life Sci 831:85-90. 2006..The method was successfully applied to the determination of pharmacokinetic parameters of esomeprazole and the two major metabolites after a single dose and under steady state conditions...
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liverAnne T Nies
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Hepatology 50:1227-40. 2009..This indicates consequences for hepatic elimination of and response to OCT substrates such as metformin...
Sensitive method for the quantification of urinary pyrimidine metabolites in healthy adults by gas chromatography-tandem mass spectrometryUte Hofmann
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
J Chromatogr B Analyt Technol Biomed Life Sci 791:371-80. 2003..The method was used for investigating the stability of urine samples and the influence of urine collection at different times...
Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groupsElke Schaeffeler
Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tuebingen, Tuebingen, Germany
Clin Chem 54:1637-47. 2008..To avoid severe hematotoxicity in patients, determination of the TPMT (thiopurine S-methyltransferase) genotype before commencing thiopurine therapy has become accepted...
A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomesMiia Turpeinen
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Drug Metab Dispos 37:1017-24. 2009..Taken together, these studies indicate that the formation of the active metabolite of nabumetone, 6-MNA, is predominantly catalyzed by CYP1A2 in HLMs with only minor contribution of other P450s...
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colonKlaus Fellermann
Department of Internal Medicine I, Robert Bosch Hospital, 70376 Stuttgart, Germany
Am J Hum Genet 79:439-48. 2006..033). In conclusion, a lower HBD-2 gene copy number in the beta-defensin locus predisposes to colonic CD, most likely through diminished beta-defensin expression...
Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liverMarco H Hofmann
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Auerbachstrasse 112, 70376 Stuttgart, Germany
J Pharmacol Exp Ther 325:284-92. 2008..These results establish the single nucleotide polymorphism 516G>Tasthe causal sequence variation for severely decreased expression and function associated with CYP2B6*6...
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4Jan Wehkamp
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstrasse 12, Stuttgart, Germany
J Immunol 179:3109-18. 2007..This new link established between a human inflammatory bowel disease and the Wnt pathway/Tcf-4 provides a novel mechanism for pathogenesis in patients with ileal CD...
Clinical pharmacokinetics and use of infliximabUlrich Klotz
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacokinet 46:645-60. 2007....
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significanceUlrich M Zanger
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Pharmacogenomics 8:743-59. 2007..In this review, we summarize general biomolecular and pharmacological features and present a detailed up-to-date description of genetic polymorphisms, including a discussion of recent clinical applications of CYP2B6 pharmacogenetics...
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesWerner Schroth
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
J Clin Oncol 25:5187-93. 2007..We investigated the predictive value of genetic variants of CYP2D6, CYP2C19, and three other cytochrome P450 enzymes for tamoxifen treatment outcome...
Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugsAnne T Nies
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Auerbachstrasse 112, 70376 Stuttgart, Germany
Expert Opin Drug Metab Toxicol 4:545-68. 2008..Hepatobiliary elimination is a vectorial process involving uptake transporters in the basolateral hepatocyte membrane, possibly Phase I and Phase II metabolizing enzymes, and ATP-dependent efflux pumps in the apical hepatocyte membrane...
MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphismsJulia K Blievernicht
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Chem 53:24-33. 2007..Several nonsynonymous and promoter single-nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with altered hepatic expression and function, which affect drug plasma concentrations...
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformationUlrich M Zanger
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, 70376, Stuttgart, Germany
Anal Bioanal Chem 392:1093-108. 2008..In this review, we provide an up-to-date summary of the functional polymorphisms and aspects of the functional genomics of the major human drug-metabolizing cytochrome P450s, as well as their clinical significance...
Mutation screening of apical sodium-dependent bile acid transporter (SLC10A2): novel haplotype block including six newly identified variants linked to reduced expressionOlga Renner
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr 112, 70376, Stuttgart, Germany
Hum Genet 125:381-91. 2009..0157). In future studies a single tag SNP selected of this haplotype block will provide reliable genetic testing to investigate systemically the influence of the SLC10A2 haplotype for disease susceptibility and/or drug response...
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenWerner Schroth
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
JAMA 302:1429-36. 2009..The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme...
Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical studyRichard Fux
Abteilung Klinische Pharmakologie, Lehrbereich Allgemeinmedizin der Medizinischen Fakultät, and Koordinierungszentrum Klinische Studien, Universitatsklinikum Tubingen, Tubingen, Germany
Clin Pharmacol Ther 78:378-87. 2005..The adverse effects studied comprised effects related to the central nervous system, cardiovascular effects, and sexual dysfunction...
Clinical aspects of the MDR1 (ABCB1) gene polymorphismMichel Eichelbaum
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
Ther Drug Monit 26:180-5. 2004..Clinical studies on the effects of the C3435T polymorphism and drug treatment with cardiac glycosides, the immunosuppressants cyclosporine and tacrolimus, HIV protease inhibitors, and tricyclic antidepressants are discussed...
CYP2C19 polymorphism and proton pump inhibitorsUlrich Klotz
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstr 112, D 70376 Stuttgart, Germany
Basic Clin Pharmacol Toxicol 95:2-8. 2004..Therefore initial genotyping for this enzyme and higher dosage in extensive metabolizers is likely to improve the clinical efficacy of proton pump inhibitors...
Lipid-lowering response to statins is affected by CYP3A5 polymorphismKari T Kivistö
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 14:523-5. 2004..These findings suggest that CYP3A5 may be a genetic determinant of interindividual differences in response to certain statins...
A multiplex MALDI-TOF MS approach facilitates genotyping of DNA from formalin-fixed paraffin-embedded tumour specimensHeike Horn
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenet Genomics 20:598-604. 2010....
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out miceKari T Kivistö
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
Naunyn Schmiedebergs Arch Pharmacol 370:124-30. 2004..As several statins are P-glycoprotein substrates, beneficial as well as adverse effects of the statins might be affected by interindividual differences in P-glycoprotein expression or function caused by, e.g., the MDR1 polymorphism...
Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variantsElke Schaeffeler
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 14:407-17. 2004..Thus, the results of this study provide a solid basis to predict TPMT phenotype in a Northern European Caucasian population by molecular diagnostics...
Topical delivery of therapeutic agents in the treatment of inflammatory bowel diseaseUlrich Klotz
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Adv Drug Deliv Rev 57:267-79. 2005..It can be assumed that for any novel therapeutic principle in IBD the approach of topical delivery will be also tried...
Organic Cation Transporters (OCTs, MATEs), In Vitro and In Vivo Evidence for the Importance in Drug TherapyAnne T Nies
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376, Stuttgart, Germany
Handb Exp Pharmacol 201:105-67. 2011....
Pharmacogenetics of antimalarial drugs: effect on metabolism and transportReinhold Kerb
Pharmacogenetics, Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Lancet Infect Dis 9:760-74. 2009..Variation in the expression of drug-metabolising enzymes and transport proteins affects the pharmacology of antimalarial drugs. Exploration of pharmacogenetics might help to optimise the use of antimalarial drugs...
CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE StudyKari T Kivistö
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Am J Pharmacogenomics 5:191-5. 2005..The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension...
Thiopurine S-methyltransferase as a target for drug interactionsHua-Wen Xin
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376, Stuttgart, Germany
Eur J Clin Pharmacol 61:395-8. 2005..This possibility should be taken into consideration if the diuretic and AZA or 6-mercaptopurine are coadministered. However, the extrapolation to the clinical setting remains open...
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17Mikko Niemi
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenet Genomics 15:303-9. 2005..The aim was to investigate whether polymorphisms in the SLCO1B1 gene, encoding the hepatic uptake transporter OATP1B1, influence the short-term effects of pravastatin on cholesterol synthesis...
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expressionJ Wehkamp
Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
Gut 53:1658-64. 2004..Paneth cells also express NOD2. To address the hypothesis that the function of NOD2 may affect expression of Paneth cell defensins, we compared their expression levels with respect to NOD2 mutations in Crohn's disease...
Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidineTanja Richter
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
J Pharmacol Exp Ther 308:189-97. 2004..These results suggest the possibility of drug interactions between thienopyridine derivates and drug substrates of CYP2B6 and CYP2C19...
Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancerMalgorzata Jaremko
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Tubingen, Stuttgart, Germany
Pharmacogenet Genomics 17:529-38. 2007..Therefore, we tested the hypothesis of a relationship between event-free survival and genotype distributions of seven polymorphic DNA repair enzymes and four cell cycle regulators...
Sex is a major determinant of CYP3A4 expression in human liverRenzo Wolbold
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany
Hepatology 38:978-88. 2003..John's wort was found. In conclusion, sex, in addition to PXR and drug exposure, is a major factor for CYP3A4 expression in humans, thus explaining many of the previous observations of sex-dependent drug clearance...
Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reactionKarin Endrizzi
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
Anal Biochem 300:121-31. 2002..46, P < 0.0001) but did not depend on CYP2D6 genotype. These data demonstrate genotype-dependent mRNA expression for CYP2D6 and they emphasize the necessity of differentiating between the functional CYP2D6 and the CYP2D pseudogenes...
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadineSiegfried Drescher
Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
Br J Clin Pharmacol 53:526-34. 2002..These data indicate that other mechanisms including uptake transporter function are likely to play a role in fexofenadine disposition...
Pulmonary delivery and tissue distribution of aerosolized antisense 2'-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lungM Dong
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Germany
Eur J Pharm Biopharm 81:478-85. 2012..No prominent changes in lung physiology parameters were observed following inhalation, suggesting good local tolerability of OMR-nanoplex formulation...
Telomeres in neonates: new insights in fetal hematopoiesisU Friedrich
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and Robert Bosch Hospital, Department of Pathology, Robert Bosch Hospital, 70376 Stuttgart, Germany
Pediatr Res 49:252-6. 2001..The initial decrease in telomere restriction fragment could be caused by ontogeny-related functional alterations of hematopoietic cells or differences in stem cell turnover or the rate of telomere loss per cell division...
Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometryT E Mürdter
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, D 70376 Stuttgart, Germany
Clin Chem 47:1437-42. 2001....
Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel diseaseH Xin
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Aliment Pharmacol Ther 21:1105-9. 2005..However, the therapeutic impact should be proved by clinical studies...
6-thioguanine--efficacy and safety in chronic active Crohn's diseaseK R Herrlinger
Robert Bosch Hospital, Stuttgart, Germany
Aliment Pharmacol Ther 17:503-8. 2003..The direct use of 6-thioguanine may offer a more rapid and safer alternative. We conducted an open prospective study to investigate the efficacy and safety of 6-thioguanine in chronic active Crohn's disease...
A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start siteJörg Zukunft
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Mol Pharmacol 67:1772-82. 2005..Furthermore, a detailed interspecies comparison of CYP2B promoters and transcriptional start sites provided novel insights into evolutionary relationships...
Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled studyDagmar Busse
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Eur J Clin Pharmacol 62:613-9. 2006..CONCLUSIONS: (S)-verapamil was about 20 times more potent than (R)-verapamil with regard to negative dromotropic effects on AV node conduction. (R)-verapamil but not (S)-verapamil significantly reduced the MAP as compared with placebo...
Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosingAlexander Teml
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Clin Pharmacokinet 46:187-208. 2007..To improve response rates in thiopurine therapy of IBD, comprehensive analyses including metabolic patterns and genome-wide profiling in patients with azathioprine/mercaptopurine treatment are required to identify novel candidate genes...
A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancerJulia Beisner
Department of Clinical Chemistry, Robert Bosch Hospital, Auerbachstrasse 110, 70376 Stuttgart, Germany
Cancer Res 66:7554-61. 2006..18; 95% confidence interval, 1.44-18.62). We provide evidence that the TGFB2 -246ins polymorphism leads to enhanced TGF-beta(2) expression levels in vivo and might thereby contribute to tumor progression and development of metastases...
Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitisKlaus R Herrlinger
Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
Inflamm Bowel Dis 10:229-33. 2004..In addition, because standard laboratory inflammatory parameters are poorly correlated with disease activity in IBD, the relation between PCT levels and disease activity was investigated...
Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-basedTanja Richter
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstr. 112, 70376 Stuttgart, Germany
Biochem Pharmacol 69:517-24. 2005..These findings contribute to better understanding of drug interactions with thioTEPA...
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liverT Lang
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Pharmacogenetics 11:399-415. 2001..These data demonstrate that the extensive interindividual variability of CYP2B6 expression and function is not only due to regulatory phenomena, but also caused by a common genetic polymorphism...
Association of SGK1 gene polymorphisms with type 2 diabetesMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Cell Physiol Biochem 21:151-60. 2008..032; OR 4.31, 95% CI 1.19-15.58) more frequent in diabetic patients (7.2 %) than in healthy volunteers from Romania (1.8%). The observations support the view that SGK-1 may participate in the pathogenesis of metabolic syndrome...
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitisMichael Gersemann
Department of Internal Medicine I, Robert Bosch Hospital, Stuttgart, Germany
Differentiation 77:84-94. 2009..Conspicuously, inflammation is associated with an enhanced goblet cell differentiation in CD but not in UC, a defect possibly of pathogenic importance...
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study GroupMatthias Schwab
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, University of Stuttgart, Stuttgart, Germany
J Clin Oncol 26:2131-8. 2008....
Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?Susanne Karner
Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart and University of Tuebingen, Tuebingen, Germany
Ther Drug Monit 32:119-28. 2010..The question whether interindividual variability of NDPK activity may explain differences in 6-thioguanosine 5'-phosphates levels has to be investigated in a prospective large-scale study...
Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinasesHeiko van der Kuip
Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
Am J Pharmacogenomics 5:101-12. 2005..This article reviews the current knowledge of clinical resistance to small molecule inhibitors approved for treatment of cancer patients...
Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazineKarin Dilger
Dr Falk Pharma GmbH, Freiburg, Germany
Ther Drug Monit 29:1-5. 2007..4. In a well-standardized clinical setting of inflammatory bowel disease, neither mesalazine nor azathioprine significantly affected TPMT activity during a whole year of treatment...
Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemiaMartin Stanulla
Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
JAMA 293:1485-9. 2005..Thiopurine methyltransferase (TPMT) is involved in the metabolism of mercaptopurine and subject to genetic polymorphism, with heterozygous individuals having intermediate and homozygous mutant individuals having very low TPMT activity...
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantationIngeborg A Hauser
Department of Nephrology, Medical Clinic IV, University Hospital Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60596 Frankfurt am Main, Germany
J Am Soc Nephrol 16:1501-11. 2005..4; 95% confidence interval, 1.2 to 148; P = 0.034). A dominant role of the donor's ABCB1 genotype was identified for development of CsA nephrotoxicity. This suggests that P-glycoprotein is an important factor in CsA nephrotoxicity...
Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteersJulia Kirchheiner
Institute of Clinical Pharmacology, Charit, Humboldt University of Berlin, Germany
Pharmacogenetics 14:19-26. 2004..However, regarding phenprocoumon hydroxylation CYP2C9 genotypes had only marginal effects on S- and R-phenprocoumon total clearance in healthy volunteers...
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null allelesThomas Lang
EPIDAUROS Biotechnologie AG, AM Neuland, Bernried, Germany
J Pharmacol Exp Ther 311:34-43. 2004..6% in a Caucasian study population. These data provide further insight into the genetic variability of CYP2B6 and demonstrate the existence of phenotypic null alleles in this gene...
Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heartPeter Dazert
Department of Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany
Am J Pathol 163:1567-77. 2003..Therefore, MRP5-mediated cellular export may represent a novel, disease-dependent pathway for cGMP removal from cardiac cells...
GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemiaMartin Stanulla
Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
Int J Hematol 81:39-44. 2005..These results suggested a modulating role for host genetic variation in the development of CNS relapse in childhood ALL treated according to Berlin-Frankfurt-Münster protocols...
Determinants of non-response in Helicobacter pylori eradication trialsUlrich Klotz
J Gastroenterol Hepatol 20:1471. 2005
The pharmacogenetics of methotrexate in inflammatory bowel diseaseKlaus R Herrlinger
Gastroenterology Unit, University of Oxford, Gibson Laboratories, Radcliffe Infirmary, Oxford, UK
Pharmacogenet Genomics 15:705-11. 2005..An individual's response to MTX may in part be genetically determined by functional genetic variation in genes encoding these enzymes. We report a pharmacogenetic evaluation of MTX therapy in IBD...
Reduced Paneth cell alpha-defensins in ileal Crohn's diseaseJan Wehkamp
Department of Microbiology and Immunology, School of Medicine, University of California, Davis, 95616, USA
Proc Natl Acad Sci U S A 102:18129-34. 2005..Thus, the specific deficiency of PC defensins that characterizes ileal CD may compromise innate immune defenses of the ileal mucosa and initiate and/or perpetuate this disease...
NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's diseaseSieglinde Angelberger
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria
Am J Gastroenterol 103:1197-202. 2008..The aim of the study was to explore systematically the association between NOD2/CARD15 variants and clinical response of perianal fistulas in patients using antibiotic therapy...
